NCT04879329 2026-01-07A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2Seagen Inc.Phase 2 Recruiting372 enrolled
NCT05302284 2023-12-18A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial CarcinomaRemeGen Co., Ltd.Phase 3 Recruiting452 enrolled